This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the blood. The study is specifically for patients who have been newly diagnosed and are eligible for a procedure called stem cell transplantation. The trial will explore the safety and effectiveness of different treatment combinations that include medications such as teclistamab and talquetamab. These medications are given through an injection under the skin, known as a subcutaneous injection. Another medication involved in the study is lenalidomide, which is taken orally in the form of a capsule. Additionally, the study will look at the use of daratumumab, which is also administered as an injection.
The purpose of the study is to evaluate how safe and tolerable these medication combinations are for patients with newly diagnosed Multiple Myeloma. Participants in the study will receive these treatments over a period of time, and the researchers will monitor them to see how their bodies respond. The study will also assess how well these treatments work in controlling the disease and improving the patients’ health. The trial will include different groups of participants, each receiving a specific combination of the medications mentioned.
Throughout the study, participants will undergo regular check-ups and tests to ensure their safety and to gather information on the effectiveness of the treatments. The study aims to provide valuable insights into how these medication combinations can be used to treat Multiple Myeloma, potentially leading to better treatment options for patients in the future.
Germany 
